Unintended and in situ amorphisation of pharmaceuticals

P A Priemel; H Grohganz; T Rades

doi:10.1016/j.addr.2015.12.014

Unintended and in situ amorphisation of pharmaceuticals

18 Citations (Scopus)

Abstract

Amorphisation of poorly water-soluble drugs is one approach that can be applied to improve their solubility and thus their bioavailability. Amorphisation is a process that usually requires deliberate external energy input. However, amorphisation can happen both unintentionally, as in process-induced amorphisation during manufacturing, or in situ during dissolution, vaporisation, or lipolysis. The systems in which unintended and in situ amorphisation has been observed normally contain a drug and a carrier. Common carriers include polymers and mesoporous silica particles. However, the precise mechanisms by which in situ amorphisation occurs are often not fully understood. In situ amorphisation can be exploited and performed before administration of the drug or possibly even within the gastrointestinal tract, as can be inferred from in situ amorphisation observed during in vitro lipolysis. The use of in situ amorphisation can thus confer the advantages of the amorphous form, such as higher apparent solubility and faster dissolution rate, without the disadvantage of its physical instability.

Original language	English
Journal	Advanced Drug Delivery Reviews
Volume	100
Pages (from-to)	126-32
Number of pages	7
ISSN	0169-409X
DOIs	https://doi.org/10.1016/j.addr.2015.12.014
Publication status	Published - 1 May 2016

Keywords

Journal Article
Review

Access to Document

10.1016/j.addr.2015.12.014

Cite this

@article{01992f88d3c44caa98bfc50be0dae9eb,

title = "Unintended and in situ amorphisation of pharmaceuticals",

abstract = "Amorphisation of poorly water-soluble drugs is one approach that can be applied to improve their solubility and thus their bioavailability. Amorphisation is a process that usually requires deliberate external energy input. However, amorphisation can happen both unintentionally, as in process-induced amorphisation during manufacturing, or in situ during dissolution, vaporisation, or lipolysis. The systems in which unintended and in situ amorphisation has been observed normally contain a drug and a carrier. Common carriers include polymers and mesoporous silica particles. However, the precise mechanisms by which in situ amorphisation occurs are often not fully understood. In situ amorphisation can be exploited and performed before administration of the drug or possibly even within the gastrointestinal tract, as can be inferred from in situ amorphisation observed during in vitro lipolysis. The use of in situ amorphisation can thus confer the advantages of the amorphous form, such as higher apparent solubility and faster dissolution rate, without the disadvantage of its physical instability.",

keywords = "Journal Article, Review",

author = "Priemel, {P A} and H Grohganz and T Rades",

year = "2016",

month = may,

day = "1",

doi = "10.1016/j.addr.2015.12.014",

language = "English",

volume = "100",

pages = "126--32",

journal = "Advanced Drug Delivery Reviews",

issn = "0169-409X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Unintended and in situ amorphisation of pharmaceuticals

AU - Priemel, P A

AU - Grohganz, H

AU - Rades, T

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Amorphisation of poorly water-soluble drugs is one approach that can be applied to improve their solubility and thus their bioavailability. Amorphisation is a process that usually requires deliberate external energy input. However, amorphisation can happen both unintentionally, as in process-induced amorphisation during manufacturing, or in situ during dissolution, vaporisation, or lipolysis. The systems in which unintended and in situ amorphisation has been observed normally contain a drug and a carrier. Common carriers include polymers and mesoporous silica particles. However, the precise mechanisms by which in situ amorphisation occurs are often not fully understood. In situ amorphisation can be exploited and performed before administration of the drug or possibly even within the gastrointestinal tract, as can be inferred from in situ amorphisation observed during in vitro lipolysis. The use of in situ amorphisation can thus confer the advantages of the amorphous form, such as higher apparent solubility and faster dissolution rate, without the disadvantage of its physical instability.

AB - Amorphisation of poorly water-soluble drugs is one approach that can be applied to improve their solubility and thus their bioavailability. Amorphisation is a process that usually requires deliberate external energy input. However, amorphisation can happen both unintentionally, as in process-induced amorphisation during manufacturing, or in situ during dissolution, vaporisation, or lipolysis. The systems in which unintended and in situ amorphisation has been observed normally contain a drug and a carrier. Common carriers include polymers and mesoporous silica particles. However, the precise mechanisms by which in situ amorphisation occurs are often not fully understood. In situ amorphisation can be exploited and performed before administration of the drug or possibly even within the gastrointestinal tract, as can be inferred from in situ amorphisation observed during in vitro lipolysis. The use of in situ amorphisation can thus confer the advantages of the amorphous form, such as higher apparent solubility and faster dissolution rate, without the disadvantage of its physical instability.

KW - Journal Article

KW - Review

U2 - 10.1016/j.addr.2015.12.014

DO - 10.1016/j.addr.2015.12.014

M3 - Journal article

C2 - 26724250

SN - 0169-409X

VL - 100

SP - 126

EP - 132

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

ER -

Unintended and in situ amorphisation of pharmaceuticals

Abstract

Keywords

Access to Document

Fingerprint

Cite this